Research study into treatment for keratoconus and corneal ectasia

Article

A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia.

A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia.

This research study will reveal whether there are any differences between the two riboflavin preparations during UV administration. The first preparation involves riboflavin in a dextran solution, which could keep the cornea thinner by removing water. In the second preparation riboflavin in a hypotonic solution will be used, which could keep the cornea more swollen.

The main goal of the study is to determine if the use of hypotonic riboflavin will help to maintain consistent corneal thickness during CXL. The secondary aim is to find out whether or not maintenance of the corneal thickness will benefit the reliability of the procedure, decrease corneal haze formation and improve safety of the endothelial cells.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.